New drug metabolism study launches for stubborn blood cancers

NCT ID NCT07444268

Recruiting now Knowledge-focused Sponsor: Sumitomo Pharma America, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the body absorbs, breaks down, and gets rid of an experimental drug called DSP-5336. It involves 8 adults with advanced blood cancers (like leukemia or myeloma) that no longer respond to standard treatments. Participants take a single radioactive-labeled pill, and researchers measure the drug in blood, urine, and stool. The goal is only to understand the drug's path through the body, not to treat the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia hematopoietic and lymphoid system neoplasm myelodysplastic syndrome myeloproliferative neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEMATOLOGIC MALIGNANCIES

Contacts and locations

Show contact details

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of North Carolina
NOT_YET_RECRUITING

Chapel Hill, North Carolina, 27514, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.